Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

EURECA EURopean Epitranscriptomics of Cancer Academy

Coordinator
Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
Runs
1 November 2025 to 31 October 2029
Status
Running
EU funding
€4.2m
Total cost
—
Partners
19 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101226733

What the project is doing

In the project's own words, from its summary on CORDIS.

The overarching objective of EURECA - The European Epitranscriptomics of Cancer Academy, is to train young doctoral candidatesinto excellence at the frontiers of basic and translational research by exploiting the cancer epitranscriptome to answer unmet clinicalneeds in cancer diagnosis, prognosis, and therapeutics and to drive change through knowledge and research. Epitranscriptomics is a new science field that studies RNA modifications (epitranscriptomic marks) and their function in regulation ofgene expression.

It is long known that many different RNA modifications exist. Yet, the true dimensions of the epitranscriptome wereunveiled only in the last decade. It is now evident that RNA modifications affect the stability, function, subcellular localization andeven immunogenicity of RNA to modulate essential cell programs like cell proliferation, differentiation, and stress response. Pathological changes in the epitranscriptome are seen as a new cancer hallmark: an independent mode of genetic reprogrammingshaping cancer’s cell fate.

We thus foresee that the epitranscriptome will prove to be a fundamental layer of gene regulationamenable to the clinics as a valuable tool in cancer diagnosis, prognosis and therapy. Focusing on RNA methylation and RNA editing in three different cancers, EURECA’s doctoral candidates will investigate thecommonalities and differences in the epitranscriptomic landscape and underlying mechanisms, while searching for novel biomarkersand treatment strategies to combat cancer and while expanding the epitranscriptomics toolbox.

The candidates will join a purposelyestablished European network of outstanding academic groups and innovative biotech companies devoted to advancing thefundamental knowledge of RNA modifications and its translation to innovative solutions for patient care. The EURECA DoctoralNetwork is the first European effort to challenge the uncharted territory of the epitranscriptome for the benefit of cancer patients.

Who is involved

OrganisationCityCountryRole
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsCoordinator
Lexogen GmbHWienAustriaAssociatedpartner
Medizinische Universitaet WienWienAustriaParticipant
Open Science - Lebenswissenschaften Im DialogWienAustriaAssociatedpartner
Universite Libre De BruxellesBruxellesBelgiumParticipant
Johannes Gutenberg-Universitat MainzMainzGermanyParticipant
Flomics Biotech SLBarcelonaSpainParticipant
Fundacio Centre De Regulacio GenomicaBarcelonaSpainParticipant
Universidad Pompeu FabraBarcelonaSpainAssociatedpartner
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Universite De LorraineNancy CedexFranceParticipant
Universite De MontpellierMontpellierFranceAssociatedpartner
Universite Lyon 1 Claude BernardVilleurbanne CedexFranceParticipant
Universita Degli Studi Di Bari Aldo MoroBariItalyParticipant
Universita Degli Studi Di TrentoTrentoItalyParticipant
Stichting European Urological FoundationArnhemNetherlandsAssociatedpartner
Instituto Portugues De Oncologia Do Porto Francisco Gentil, EpePortoPortugalParticipant
Universidade Do PortoPortoPortugalAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS